NCT06245213

A Study of ANAVEX3-71 in Adults With Schizophrenia

Name: Clinical Trial NCT06245213
Creator: Anavex Life Sciences Corp.
Keywords: Schizophrenia, ANAVEX3-71 oral capsules, Phase 2, drug, clinical trial, United States of America

A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Electrophysiology of ANAVEX3-71 in Adult Patients With Schizophrenia in a Multiple Ascending Dose Study (Part A), Followed by a Double-Blind, Randomized, Placebo-Controlled Study (Part B)

Anavex Life Sciences Corp.·Phase 2·ClinicalTrials.gov·drugRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Schizophrenia
Drug/Device/Intervention: ANAVEX3-71 oral capsules
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Anavex Life Sciences Corp.
Location: Marlton, United States of America

Timeline & enrollment

Phase: Phase 2
Start date: Mar 15, 2024
End date: May 15, 2025
Enrollment: 40 participants

Primary outcome

Single Dose Maximum Observed Plasma Concentration (Cmax),Multiple Dose Maximum Observed Plasma Concentration (Cmax),Cmax (steady state),Tmax (steady state),AUC (steady state),AUC (single state),CL/F (steady state),Vz/F (steady state),T1/2 (steady state),Rac (steady state),Rac, Cmax (steady state),PTR (steady state),Adverse Events,Vital Signs,12-lead ECG (RR interval),12-lead ECG (P wave),12-lead ECG (PR interval),12-lead ECG (PR segment),12-lead ECG (QRS complex),12-lead ECG (ST segment),12-lead ECG (T wave),12-lead ECG (QT interval),Clinical Safety Labs - Renal Panel,Clinical Safety Labs - Hepatic Panel,Clinical Safety Labs - Lipid Panel,Clinical Safety Labs - Hematology Panel,Clinical Safety Labs - Urinalysis Panel,Clinical Safety Labs - Coagulation Panel,Brief Physical Examination,Brief Neurological Examination,AIMS,SAS,BARS,CDSS,C-SSRS,EEG-ERP - Passive, Duration Deviant, Oddball ERP,EEG-ERP - Active, Auditory, Oddball ERP,EEG-ERP - Auditory Steady State Response,EEG-ERP - Resting EEG

Summary

A study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and electrophysiology of ANAVEX3-71 in patients with Schizophrenia.

ICD-10 classifications

SchizophreniaSimple schizophreniaSchizophrenia, unspecifiedOther schizophreniaParanoid schizophrenia

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06245213
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06245213 through Pure Global AI's free database. This Phase 2 trial is sponsored by Anavex Life Sciences Corp. and is currently Recruiting. The study focuses on Schizophrenia. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.